A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

• Status: Terminated
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma US, Inc.
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney.

• Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure.

Exclusion Criteria:

• Patient has received or is receiving an organ transplant other than kidney

• Patient has received a kidney transplant from a cadaveric donor >= 60 years of age.